|
|
| | 3-Azetidinecarboxylic acid, 1-[[5-[1-[[4-chloro-3-(trifluoromethyl)phenyl]ethylamino]ethyl]-2-methylphenyl]methyl]- Basic information |
| | 3-Azetidinecarboxylic acid, 1-[[5-[1-[[4-chloro-3-(trifluoromethyl)phenyl]ethylamino]ethyl]-2-methylphenyl]methyl]- Chemical Properties |
| Boiling point | 559.9±50.0 °C(predicted) | | density | 1.311±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 2.70±0.20(predicted) |
| | 3-Azetidinecarboxylic acid, 1-[[5-[1-[[4-chloro-3-(trifluoromethyl)phenyl]ethylamino]ethyl]-2-methylphenyl]methyl]- Usage And Synthesis |
| Uses | KSI-6666 is an orally active, competitive antagonist for sphingosine 1-phosphate receptor 1 (S1PR1), with an IC50 of 6.4 nM. KSI-6666 exhibits anti-inflammatory efficacy in autoimmune encephalomyelitis model and T cell transfer colitis model[1]. | | IC 50 | S1PR1: 6.4 nM (IC50) | | References | [1] Maruyama Y, et al. Pseudoirreversible inhibition elicits persistent efficacy of a sphigosine-1-phosphate receptor-1 antagonist[J]. bioRxiv, 2023: 2023.05. 08.539826. |
| | 3-Azetidinecarboxylic acid, 1-[[5-[1-[[4-chloro-3-(trifluoromethyl)phenyl]ethylamino]ethyl]-2-methylphenyl]methyl]- Preparation Products And Raw materials |
|